SeeTreat welcomes new Board directors

SeeTreat, a software medical device company with a vision to 'turn on the light' for oncology treatments enabling affordable personalised and precise treatment for every patient, is pleased to announce new Board directors as SeeTreat prepares for commercial release of its first products to clinics. We welcome Dr Richard Hausmann, Associate Professor Tee Lim and Dr Shane La Bianca to our Board from October 2024. They will join existing executive Board members Dr Trang Nguyen (CEO and Co-Founder), Professor Paul Keall (Co-Founder) and Antonia Dalton (Chief Strategy Officer).

Dr Richard Hausmann brings decades of experience in the medtech industry in both publicly listed companies and start-ups in multiple jurisdictions globally. His experience spans GE's Magnetic Resonance division as President and CEO and holding several senior positions at Siemens over more than twenty years. Until recently he was global CEO of Elekta, one of the largest radiation therapy device manufacturer in the world, and has also served as CEO of Combinostics, which uses AI technology to manage the care pathway and improve the lives of patients with neurological disorders. Richard is a member of the board of directors of IBA SA, a global market leader in proton therapy.

Associate Professor Tee Lim is a leading Australian radiation oncologist with a diverse clinical interest in breast, urological cancers, gastrointestinal and lung cancers. He has a broad clinical practice with experience in Canada and the US completing fellowships at both Sunnybrook Toronto and at the University of California, San Francisco Medical Centre. In addition to his oncology work, A/Prof Lim is pioneering in specialised cardiac treatments such as cardiac ablation therapy for cardiac arrythmia and total lymphoid irradiation for cardiac transplantation rejection in Western Australia. As a clinical associate professor at the University of Western Australia, he has made significant contribution to cancer research, co-authoring over 40 published papers and abstracts. He is actively involved in clinical trials, and regularly presents at scientific meetings.

Dr La Bianca is a Urologist with international experience in Australia and Vancouver, Canada. He is an adjunct senior lecturer at the University of Notre Dame. He has over 25 years of clinical uro-oncology experience in the management of bladder and prostate cancer, PSA and hormonal therapy. A self- proclaimed technophile, Dr La Bianca offers a different perspective on SeeTreat technology and the potential applications to improve interventional treatments beyond radiotherapy.

Together these independent Directors will bring new insights to SeeTreat to support us at this critical juncture of taking product from development to clinical practice.

SeeTreat has grown from 2 to 15 full time employees in 18 months and is planning to release two SeeTreat products to market in 2024. The Company has successfully raised over $6m in capital executed two commercial partnerships in Australia and the US. This success is a testament to the market need for our products, our software development team's delivery capability, and our opportunity to truly improve patient outcomes through more precise and personalised radiotherapy treatments. We're looking forward to the next 12 months to focus on getting these products into the hands of the clinical teams and making an impact on patients' lives.